{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:06:27Z","timestamp":1792317987034,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ekir.2020.03.030","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T19:47:02Z","timestamp":1586893622000},"page":"879-890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)"],"prefix":"10.1016","volume":"5","author":[{"given":"Masaomi","family":"Nangaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Takama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2020.03.030_bib1","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2020.03.030_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10157-009-0199-x","article-title":"Prevalence of chronic kidney disease in the Japanese general population","volume":"13","author":"Imai","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2020.03.030_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ki.2012.439","article-title":"Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease","volume":"83","author":"Ruiz","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.03.030_bib4","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Dinkova-Kostova","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2020.03.030_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-06-0516","article-title":"Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes","volume":"6","author":"Yates","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ekir.2020.03.030_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/np100826q","article-title":"New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress","volume":"74","author":"Sporn","year":"2011","journal-title":"J\u00a0Nat Prod"},{"key":"10.1016\/j.ekir.2020.03.030_bib7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ekir.2020.03.030_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000327599","article-title":"Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD","volume":"33","author":"Pergola","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2020.03.030_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.03.030_bib10","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.03.030_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000362906","article-title":"Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"39","author":"Chin","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2020.03.030_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","article-title":"Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"20","author":"Chin","year":"2014","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.ekir.2020.03.030_bib13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.03.030_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.ekir.2020.03.030_bib16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2012.393","article-title":"The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells","volume":"83","author":"Ding","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.03.030_bib17","doi-asserted-by":"crossref","first-page":"31579","DOI":"10.1074\/jbc.M109.009175","article-title":"Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels","volume":"284","author":"Heiss","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2020.03.030_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.redox.2013.10.007","article-title":"The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease","volume":"1","author":"Aminzadeh","year":"2013","journal-title":"Redox Biol"},{"key":"10.1016\/j.ekir.2020.03.030_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/00498254.2013.852705","article-title":"The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease","volume":"44","author":"Aminzadeh","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ekir.2020.03.030_bib20","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.2337\/db13-1743","article-title":"Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease","volume":"63","author":"Tan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ekir.2020.03.030_bib21","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2020.03.030_bib22","doi-asserted-by":"crossref","unstructured":"Kidokoro K, Nagasu H, Satoh M, et\u00a0al. Activation of the Keap1\/Nrf2 pathway increases GFR by increasing glomerular effective filtration area without affecting the afferent\/efferent arteriole ratio. Poster presented at: ASN Kidney Week 2019; November 5\u201310, 2019; Washington, DC.","DOI":"10.1093\/ndt\/gfaa142.P0089"},{"key":"10.1016\/j.ekir.2020.03.030_bib23","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.kint.2019.04.027","article-title":"Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease","volume":"96","author":"Rossing","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.03.030_bib24","unstructured":"Miller GA, Bumeister R, Laidlaw J, et\u00a0al. Bardoxolone methyl transcriptionally regulates transaminase levels and increases glutathione levels. Poster presented at: ASN Kidney Week 2011; November 8\u201313, 2011; Philadelphia, PA."},{"key":"10.1016\/j.ekir.2020.03.030_bib25","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jdiacomp.2018.09.005","article-title":"Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2018","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.ekir.2020.03.030_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejphar.2009.08.022","article-title":"Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide","volume":"620","author":"Shin","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ekir.2020.03.030_bib27","doi-asserted-by":"crossref","first-page":"40581","DOI":"10.1074\/jbc.M110.176545","article-title":"The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db\/db) mice","volume":"285","author":"Saha","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2020.03.030_bib28","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1128\/MCB.00225-13","article-title":"The Keap1-Nrf2 system prevents onset of diabetes mellitus","volume":"33","author":"Uruno","year":"2013","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ekir.2020.03.030_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1042\/BJ20130863","article-title":"Nrf2 affects the efficiency of mitochondrial fatty acid oxidation","volume":"457","author":"Ludtmann","year":"2014","journal-title":"Biochem J"},{"key":"10.1016\/j.ekir.2020.03.030_bib30","doi-asserted-by":"crossref","first-page":"549352","DOI":"10.1155\/2015\/549352","article-title":"Bardoxolone methyl prevents mesenteric fat deposition and inflammation in high-fat diet mice","volume":"2015","author":"Dinh","year":"2015","journal-title":"Sci World J"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920311712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920311712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:31:30Z","timestamp":1762831890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024920311712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2468024920311712"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2020.03.030","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2020.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}